Credit Suisse analyst Vamil Divan maintained a Buy rating on Allergan (NYSE: AGN) yesterday and set a price target of $213. The company’s shares closed yesterday at $171.04.
According to TipRanks.com, Divan is a 1-star analyst with an average return of -1.6% and a 44.2% success rate. Divan covers the Healthcare sector, focusing on stocks such as Aimmune Therapeutics, Johnson & Johnson, and Eli Lilly & Co.
Currently, the analyst consensus on Allergan is Moderate Buy and the average price target is $208.82, representing a 22.1% upside.
In a report issued on June 5, Wells Fargo also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Based on Allergan’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $286 million. In comparison, last year the company had a GAAP net loss of $2.57 billion.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States.
